Future Directions in Advanced RCC

Panelists discuss future directions in the treatment of advanced renal cell carcinoma (RCC), focusing on emerging therapies, clinical trials, and potential advancements in patient disease management.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.1L Treatment Landscape for Advanced Renal Cell Carcinoma

EP: 2.Metastatic Site–Specific Outcomes With 1L ccRCC Therapies

EP: 3.Clinical Decision-making With TKI-IO Combinations for Advanced RCC

EP: 4.Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns

EP: 5.Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

EP: 6.CLEAR Follow-Uup Analysis: Implications for Clinical Decision MakingDecision-Making

Now Viewing

EP: 7.Future Directions in Advanced RCC

Recent Videos

Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making

Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions

MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer

Second-Line Treatment for Gastric Adenocarcinoma

Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

Gastric Adenocarcinoma: Current Treatment Landscape

Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

Esophageal/Gastric Adenocarcinoma Standard of Care

BESPOKE: Study Design, Efficacy End Points and Methods